Literature DB >> 21859819

Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress.

Mirjana Jerkic1, Mohammed G Kabir, Adrienne Davies, Lisa X Yu, Brendan A S McIntyre, Nasir W Husain, Masahiro Enomoto, Valentin Sotov, Mansoor Husain, Mark Henkelman, Jaques Belik, Michelle Letarte.   

Abstract

AIMS: Mutations in the ALK1 gene, coding for an endothelial-specific receptor of the transforming growth factor-β superfamily, are the underlying cause of hereditary haemorrhagic telangiectasia type 2, but are also associated with familial pulmonary hypertension (PH). We assessed the lung vasculature of mice with a heterozygous deletion of Alk1 (Alk1(+/-)) for disease manifestations and levels of reactive O(2) species (ROS) implicated in both disorders. METHODS AND
RESULTS: Several signs of PH, including elevated right ventricular (RV) systolic pressure leading to RV hypertrophy, reduced vascular density, and increased thickness and outward remodelling of pulmonary arterioles, were observed in 8- to 18-week-old Alk1(+/-) mice relative to wild-type littermate controls. Higher ROS lung levels were also documented. At 3 weeks, Alk1(+/-) mice were indistinguishable from controls and were prevented from subsequently developing PH when treated with the anti-oxidant Tempol for 6 weeks, confirming a role for ROS in pathogenesis. Levels of NADPH oxidases and superoxide dismutases were higher in adults than newborns, but unchanged in Alk1(+/-) mice vs. controls. Prostaglandin metabolites were also normal in adult Alk1(+/-) lungs. In contrast, NO production was reduced, while endothelial NO synthase (eNOS)-dependent ROS production was increased in adult Alk1(+/-) mice. Pulmonary near resistance arteries from adult Alk1(+/-) mice showed less agonist-induced force and greater acetylcholine-induced relaxation; the later was normalized by catalase or Tempol treatment.
CONCLUSION: The increased pulmonary vascular remodelling in Alk1(+/-) mice leads to signs of PH and is associated with eNOS-dependent ROS production, which is preventable by anti-oxidant treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859819     DOI: 10.1093/cvr/cvr232

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  29 in total

Review 1.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

Review 2.  Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature.

Authors:  Gerald J Maarman; Rainer Schulz; Karen Sliwa; Ralph Theo Schermuly; Sandrine Lecour
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

3.  Things We "kNOw" and Do Not "kNOw" about Pulmonary Hypertension.

Authors:  Jarrod W Barnes; Rakesh P Patel
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

4.  Novel protein interactions with endoglin and activin receptor-like kinase 1: potential role in vascular networks.

Authors:  Guoxiong Xu; Miriam Barrios-Rodiles; Mirjana Jerkic; Andrei L Turinsky; Robert Nadon; Sonia Vera; Despina Voulgaraki; Jeffrey L Wrana; Mourad Toporsian; Michelle Letarte
Journal:  Mol Cell Proteomics       Date:  2013-12-07       Impact factor: 5.911

5.  Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.

Authors:  Joshua P Fessel; Charles R Flynn; Linda J Robinson; Niki L Penner; Santhi Gladson; Christie J Kang; David H Wasserman; Anna R Hemnes; James D West
Journal:  Am J Respir Cell Mol Biol       Date:  2013-11       Impact factor: 6.914

6.  Organ specific optical imaging of mitochondrial redox state in a rodent model of hereditary hemorrhagic telangiectasia-1.

Authors:  Zahra Ghanian; Sepideh Maleki; SunYoung Park; Christine M Sorenson; Nader Sheibani; Mahsa Ranji
Journal:  J Biophotonics       Date:  2013-06-06       Impact factor: 3.207

7.  Interventions and mechanisms of N-acetylcysteine on monocrotaline-induced pulmonary arterial hypertension.

Authors:  Wencheng Yu; Xiaoxia Song; Chen Lin; Weina Ji
Journal:  Exp Ther Med       Date:  2018-04-27       Impact factor: 2.447

Review 8.  Endothelial and Smooth Muscle Cell Interactions in the Pathobiology of Pulmonary Hypertension.

Authors:  Yuansheng Gao; Tianji Chen; J Usha Raj
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

9.  Transcriptomic analysis of pulmonary artery smooth muscle cells identifies new potential therapeutic targets for idiopathic pulmonary arterial hypertension.

Authors:  Matthew W Gorr; Krishna Sriram; Abinaya Muthusamy; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-05-15       Impact factor: 8.739

Review 10.  Targeting BMP signalling in cardiovascular disease and anaemia.

Authors:  Nicholas W Morrell; Donald B Bloch; Peter ten Dijke; Marie-Jose T H Goumans; Akiko Hata; Jim Smith; Paul B Yu; Kenneth D Bloch
Journal:  Nat Rev Cardiol       Date:  2015-10-13       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.